Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 51Oligometastatic Prostate Cancer 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Prostate CA 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Non-metastatic, Hormone naïve Prostate Cancer 1Lymphatic Metastasis 1Hormone Sensitive Prostate Cancer 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Radiotherapy, Intensity-Modulated 3Cisplatin 2encorafenib 1binimetinib 1alovudine 1X-Rays 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radiation Dose Hypofractionation 1Platinum 1Nivolumab 1Metastasectomy 1Magnetic Resonance Spectroscopy 1Leuprolide 1Ipilimumab 1Goserelin 1Drug Therapy 1Docetaxel 1Axitinib 1Androgen Antagonists 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphatic Metastasis × Androgen Antagonists × Clear all
NCT01409200 2026-03-03

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

M.D. Anderson Cancer Center

Phase 2 Completed
73 enrolled

Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡